1.Click Chemistry in Human Cancer Research
Cancer Research on Prevention and Treatment 2024;51(11):951-955
As one of the typical bioorthogonal chemistry reactions, click chemistry joins molecules similar to “Lego”. Bioorthogonal click chemistry is used to modify cancer cells, design antitumor drugs, delivery drugs, manipulate immune cells, and help preclinical evaluation. Click chemistry provides a promising approach for discovering molecules and targeting cancer in cancer research.
2.Optical Tweezers in Human Cancers
Cancer Research on Prevention and Treatment 2024;51(4):296-299
Optical tweezers are a means to manipulate objects with light. Optical tweezers can obtain a nanometer space, piconewton force, and a millisecond resolution; thus, they are excellently suited for studying biological processes from the single-cell to the single-molecule level. Optical tweezers can screen and manipulate tumor cells, study single molecule, and monitor cancer treatments. Thus, optical tweezers will promote the progress of cancer research and treatments.
3.Differentiation therapies in human cancers
Journal of International Oncology 2024;51(2):109-113
Cancer phenotypic plasticity includes dedifferentiation, blocked differentiation and trans- differentiation, and differentiation therapy targeting tumor cell plasticity is becoming a new therapeutic model for human cancers. The application of inducing differentiation, initiating differentiation and regulating differentiation in tumor differentiation therapy will promote the directed differentiation of tumor cells into mature cells and the remodeling of phenotypes, thus to achieve the purpose of cancer treatment.
4.Advances in anti-tumor drugs with new mechanisms of action
Journal of International Oncology 2024;51(6):354-358
Cytotoxic agents, molecular targeted agents and immune checkpoint inhibitors consist of the fundamental model of cancer systematic treatments. Anti-tumor drugs with new mechanisms of action, including kinase inhibitors, therapeutic antibodies, nucleic acid blocks, therapeutic vaccines, gene-edited immune cells, living microrobots and digital drugs, will change this existing model. Drugs targrting nerves, polysaccharides, lipids and microflora may gradually enter clinical applications.
5.The role of m6 A modification in tumor autophagy
Bai JIE ; Su XIAYI ; Wei XIUZHEN ; Dong YALING ; Zhu ZHIBO ; Zhang BAIHONG
Chinese Journal of Clinical Oncology 2024;51(15):795-800
Autophagy is a cellular self-degradation process essential for maintaining metabolic functions in cells and organisms.Dysfunc-tional autophagy has been linked to various diseases,including cancer.The m6A modification,a major RNA modification in eukaryotes,plays a crucial role in regulating autophagy in tumor cells by regulating the expression of autophagy-associated genes(ATGs)or interfering with autophagy-related signaling pathways.Aberrant m6A modification can lead to dysregulated autophagy and impact tumor progression.However,the specific role of m6A in regulating tumor autophagy remains to be explored.Therefore,in this review,we discuss the role of m6A modification in tumor cell autophagy and examine its relationship with tumor progression and drug resistance,aiming to provide a the-oretical foundation for developing new therapeutic strategies.
6.Recent Insights into Mechanisms Governing Breast Cancer Dormancy
Cancer Research on Prevention and Treatment 2023;50(12):1237-1242
Tumor dormancy refers to the status of disseminated cancer cells that remain in a viable yet not proliferating state for a prolonged period. Dormant cells will eventually "re-awake" resume their proliferation, and produce overt metastasis. The dormancy mechanism of cancer has attracted attention because of the close relationship between late recurrence and tumor dormancy. In this review, we illustrate the latest discoveries on the biological underpinnings of breast cancer dormancy and offer clinicians an overview of dormancy in breast cancer to guide them in the basic understanding of the complexity that underlies this process.
7.Research progress of immune checkpoint agonist for solid tumor treatments
Journal of International Oncology 2023;50(5):290-293
Immune checkpoint consists of inhibitory and stimulatory molecules. Drugs blocking inhibitory checkpoint programmed cell death receptor-1 (PD-1) and cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) are currently utilized for wide variety of human cancers. Agonists of stimulatory checkpoints such as GITR, OX40, 4-1BB, ICOS, CD40 and STING are undergoing critical clinical trials. Immune checkpoint agonists that affect stimulatory checkpoint molecules develop rapidly, and immune agonist antibodies thus represent an important approach for solid tumor treatments.
8.Senotherapies in cancers
Journal of International Oncology 2023;50(12):734-738
Cancer cells have a senescence response, and senescence in cancer cells have both tumor-suppressive and tumor-promoting effects. Cancer senotherpy includes pro-senescent cancer therapy, senolytic therapy and senomorphic therapy. However, the efficacy and adverse effects need to be thoroughly studied. Detection of senescence-associated proteins and metabolites within the patients' cancer senescent cells and peripheral blood may help to evaluate the efficacy of senotherapy and guide future clinical trials.
9.LMX1B-associated disease presented with prominent asymptomatic proteinuria
Fang WANG ; Baihong LI ; Xiaoyu LIU ; Huijie XIAO ; Yong YAO ; Suxia WANG ; Yanqin ZHANG ; Jie DING
Chinese Journal of Applied Clinical Pediatrics 2022;37(9):706-709
Objective:To analyze clinical data of 3 children with LMX1B-associated disease characterized by asymptomatic glomerular proteinuria, thus improving the recognition of asymptomatic proteinuria with genetic causes. Methods:Three patients with LMX1B-associated disease presented with prominent asymptomatic proteinuria diagnosed by the next-generation sequencing in Department of Pediatrics, Peking University First Hospital from April 2014 to October 2017 were included in this study.Clinical data, including renal and extrarenal manifestations, renal biopsy, and family history, were collected and retrospectively analyzed. Results:All 3 children were girls, the age of onset were 2 years, 1 year, and 4 years, respectively, and the diagnosis age were 11 years, 5 years and 6 years, respectively.All of them had glomerular proteinuria, and nephrotic-level proteinuria occurred in one patient.Microscopic hematuria was found in 2 patients.All of them had normal renal function.Only one patient underwent renal biopsy.Electron microscopy of the first time of biopsy revealed segmental thinning of the glomerular basement membrane.Re-biopsy 4 years later showed irregular thickening of the glomerular basement membrane, moth-eaten appearance and collagen fibrillar material deposition.No abnormalities of nails, limbs and joints were observed by physical examination.Two patients had a family history of renal disease.Conclusions:Genetic factors should be considered in children with obscure onset asymptomatic proteinuria without definite clinical causes.Genetic testing can help diagnose and guide treatment as early as possible.
10.Analysis of the frontier and hotspot of screening technology for early lung cancer based on bibliometrics
Wei LI ; Longhao ZHANG ; Xiaoqing GONG ; Baihong LI ; Jian PU ; Taibing DENG ; Ailin WEI ; Dan LIU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2022;29(11):1478-1484
Objective To reveal and demonstrate the hotspots and further research directions in screening technology for early lung cancer, and provide references for the future studies. Methods Researches related to lung cancer screening from 2011 to 2021 in the Web of Science database were included. Biblioshiny, a bibliometrics program based on R language, was used to perform content analysis and visualization of the included literature information. Results Researches related to lung cancer screening were increasing year by year. Six major cooperation groups were formed between countries. The current research hotspots in the field of early lung cancer screening technology mainly focused on the multi-directional fusion of radiographic imaging, liquid biopsy and artificial intelligence. Conclusion Low-dose spiral CT screening is still the most important and mainstream method for the screening of early lung cancer at present. The combination and integration of artificial intelligence with various screening methods and the innovation of novel testing and diagnostic equipment are the current research hotspots and the future research trend in this field.

Result Analysis
Print
Save
E-mail